Faeth Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is FTH moving today?
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FTH.
FTH insider activity
Faeth Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $326K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-07-01 | STEPHENSON BRIAN C | Insider | buy | $24.22 | 600 | 46,688 | $15K | SEC Form 4 |
| 2026-07-01 | 2026-07-01 | STEPHENSON BRIAN C | Insider | buy | $23.40 | 4,400 | 46,088 | $103K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C | Insider | buy | $24.98 | 4,255 | 41,688 | $106K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C | Insider | buy | $23.88 | 1,638 | 37,433 | $39K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C | Insider | buy | $22.95 | 1,910 | 35,795 | $44K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFTH contract awards, year to date.
Public federal awards linked to this ticker.
FTH lobbying filings, year to date.
Registered lobbying filings matched to Faeth Therapeutics, Inc. Common Stock.